Td Asset Management Inc Ultragenyx Pharmaceutical Inc. Transaction History

Td Asset Management Inc

$107 Billion
Q3 2024

A detailed history of Td Asset Management Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 169,084 shares of RARE stock, worth $7.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

169,084

Previous 149,084 13.42%

Holding current value

$7.6 Million

Previous $6.13 Million 53.29%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$40.21 - $59.36 $804,200 - $1.19 Million	20,000 Added 13.42%	169,084 $9.39 Million
Q2 2024 Aug 02, 2024	SELL	$37.42 - $51.61 $2.67 Million - $3.68 Million	-71,276 Reduced 32.35%	149,084 $6.13 Million
Q1 2024 May 08, 2024	SELL	$43.02 - $53.69 $43,020 - $53,690	-1,000 Reduced 0.45%	220,360 $10.3 Million
Q4 2023 Feb 12, 2024	BUY	$31.73 - $49.19 $507,680 - $787,040	16,000 Added 7.79%	221,360 $10.6 Million
Q3 2023 Oct 27, 2023	BUY	$34.92 - $46.66 $3.06 Million - $4.09 Million	87,580 Added 74.36%	205,360 $7.32 Million
Q2 2023 Aug 09, 2023	BUY	$37.35 - $52.15 $709,724 - $990,954	19,002 Added 19.24%	117,780 $5.43 Million
Q1 2023 May 10, 2023	SELL	$36.99 - $48.71 $1.16 Million - $1.53 Million	-31,372 Reduced 24.1%	98,778 $3.96 Million
Q4 2022 Feb 06, 2023	SELL	$33.72 - $46.33 $4.46 Million - $6.13 Million	-132,214 Reduced 50.39%	130,150 $6.03 Million
Q3 2022 Nov 07, 2022	SELL	$39.96 - $66.14 $1.67 Million - $2.77 Million	-41,863 Reduced 13.76%	262,364 $10.6 Million
Q2 2022 Aug 04, 2022	SELL	$45.8 - $85.4 $2.48 Million - $4.62 Million	-54,114 Reduced 15.1%	304,227 $18.2 Million
Q1 2022 May 10, 2022	SELL	$62.2 - $84.4 $959,746 - $1.3 Million	-15,430 Reduced 4.13%	358,341 $26 Million
Q4 2021 Feb 10, 2022	BUY	$73.71 - $87.86 $9.57 Million - $11.4 Million	129,824 Added 53.22%	373,771 $31.4 Million
Q3 2021 Nov 09, 2021	BUY	$77.92 - $102.4 $747,019 - $981,708	9,587 Added 4.09%	243,947 $22 Million
Q2 2021 Aug 11, 2021	BUY	$92.19 - $115.71 $653,903 - $820,731	7,093 Added 3.12%	234,360 $18.7 Million
Q1 2021 May 14, 2021	BUY	$106.9 - $167.73 $5 Million - $7.85 Million	46,789 Added 25.93%	227,267 $25.9 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $3.68 Million - $7.74 Million	43,636 Added 31.89%	180,478 $25 Million
Q3 2020 Nov 10, 2020	BUY	$72.98 - $90.0 $1.93 Million - $2.39 Million	26,500 Added 24.02%	136,842 $11.2 Million
Q2 2020 Aug 13, 2020	BUY	$46.91 - $78.22 $1.84 Million - $3.08 Million	39,326 Added 55.38%	110,342 $8.63 Million
Q1 2020 May 15, 2020	SELL	$33.8 - $62.9 $1,825 - $3,396	-54 Reduced 0.08%	71,016 $3.16 Million
Q4 2019 Feb 11, 2020	SELL	$36.08 - $45.83 $147,928 - $187,903	-4,100 Reduced 5.45%	71,070 $3.04 Million
Q3 2019 Nov 07, 2019	SELL	$42.5 - $63.11 $340,000 - $504,880	-8,000 Reduced 9.62%	75,170 $3.22 Million
Q2 2019 Aug 01, 2019	BUY	$54.93 - $74.36 $1.01 Million - $1.36 Million	18,350 Added 28.31%	83,170 $5.28 Million
Q1 2019 May 08, 2019	BUY	$39.87 - $69.36 $290,293 - $505,010	7,281 Added 12.65%	64,820 $4.5 Million
Q4 2018 Feb 01, 2019	SELL	$38.89 - $77.3 $62,224 - $123,680	-1,600 Reduced 2.71%	57,539 $2.5 Million
Q3 2018 Nov 01, 2018	SELL	$71.81 - $90.15 $17,378 - $21,816	-242 Reduced 0.41%	59,139 $4.52 Million
Q2 2018 Jul 31, 2018	BUY	$48.54 - $85.31 $649,804 - $1.14 Million	13,387 Added 29.11%	59,381 $4.57 Million
Q1 2018 May 11, 2018	BUY	$44.33 - $58.52 $206,843 - $273,054	4,666 Added 11.29%	45,994 $2.35 Million
Q4 2017 Feb 02, 2018	BUY	$43.54 - $57.32 $422,338 - $556,004	9,700 Added 30.67%	41,328 $1.92 Million
Q3 2017 Nov 09, 2017	BUY	$49.79 - $66.32 $1.57 Million - $2.1 Million	31,628	31,628 $1.69 Million

Others Institutions Holding RARE

# of Institutions

326

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.15B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.

Account

Td Asset Management Inc Ultragenyx Pharmaceutical Inc. Transaction History